The Difference Between Cystatin C– and Creatinine-Based eGFR in Heart Failure With Reduced Ejection Fraction bit.ly/3NeVRHr Alberto Pinsino Ali Husain Sumit Mohan Jai Radhakrishnan Doug Jennings, Pharm.D. Austin Nguonly Lorenzo Braghieri, MD 🇮🇹🇺🇸🇪🇺 Gabriel Sayer Nir Uriel, MD MSc Melana Yuzefpolskaya @ColumbiaKidney

New paper out! About the principles that shaped MPOX research/advocacy work we did in New York City and how those are connected to principles that activists have elaborated and practiced in global health activism. journals.plos.org/globalpubliche…

Semaglutide 2.4 changing the paradigm in HFpEF in obese population ‼️ ✅ STEP HFpEF trial meets dual primary endpoint KCCQ-Clinical summary score and weight loss. ✅ Waiting for clinical endpoints. novonordisk.com/content/dam/nn…

Big news in the #amyloidosis world with the release of top line results for the Phase 3 #acoramidis trial, ATTRIBUTE-CM. Main message: It worked! 🍾 A lot of fascinating history behind this story. What else can we learn from the data? Details to follow… (1/14)

⚠️Myocardial Tissue-Level Characteristics of Adults With Metabolically Healthy Obesity (MHO) vs metabolically unhealthy obesity (MUHO) 👉 myocardial fibrosis was 44% in the MHO vs 71% in the MUHO group 👉MHO group had ⤵️ global longitudinal peak systolic and early diastolic

A new study by George Thurston found that the closure of a coal-processing plant in Pittsburgh led to near-instant decreases in air pollution. It further links the declines to drops in local heart-related ED visits & hospitalizations over a 3-year period: bit.ly/47baGTh

Despite a huge drop in cases, #Mpox isn't over. As cases continue popping up around the world, it's important to understand how #Mpox spread last summer and what worked (or didn't) to contain it. We explore global mpox dynamics in our new preprint! 🧵(1/N) medrxiv.org/content/10.110…

#SGLT2i's benefit in #HFpEF, but why and how? First in HFpEF! SGLT2i's effect on #PCWP by #RHC in a mechanistic randomized trial. #Dapa⬇️PCWP, improving the fundamental hemodynamic abnormality underlying HFpEF. Circulation Mayo Clinic Yogesh Reddy #Borlaugslab ahajournals.org/doi/10.1161/CI…

Must-read roadmapping review of device-based therapies for heart failure jacc.org/doi/10.1016/j.… JACC Journals

#Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with #HFpEF and #obesity ⬇️ #ESCCongress STEP-HFpEF trial

CKM syndrome is: -A systemic disorder -Characterized by pathophysiologic interactions among metabolic risk factors, CKD, and CV system -Leading to multiorgan dysfunction -> adverse CVD outcomes -Includes both individuals at risk for CVD and individuals with existing CVD 1/6

ARIES-HM3 Trial 📌Eliminating aspirin and using only a Vit K antagonist in #LVAD patients led to a 34% reduction in major nonsurgical 🩸. 📌No increase in thromboembolic risk observed without #aspirin. 📌Benefits consistent even in patients with higher thrombosis risk due to

⚠️#SGLT2i effect on left cardiac remodelling in #HFrEF: Systematic review and meta-analysis Six trials (👥555). Compared with control, SGLT2i significantly improved 📌 LVEDV 📌 LVESV 📌LVEF(↗️2.7 %) 📌left atrial volume index 🚫non-significant trend towards a reduction in left

“Cardiometabolic & renal traits of the US population have shifted from phenotypes with high blood pressure & cholesterol toward poor kidney function, hyperglycemia & severe obesity” nature.com/articles/s4416…

Almost 90% of US adults met criteria for cardiovascular, kidney, and metabolic syndrome (stage 1 or higher) and 15% met criteria for advanced stages, neither of which improved between 2011 and 2020. ja.ma/3wTJSd4

Tirzepatide prevents progression to type 2 diabetes by 93% in those with prediabetes and obesity🤯 📉Weight loss of 19.7% was sustained over 3 years with the highest dose. New trial results published in NEJM today nejm.org/doi/full/10.10…

🚨 New in JAMA Network Open, co-led by myself and Trisha Santos, MD, MS, examining #AsianAmerican representation in medicine! jamanetwork.com/journals/jaman… 🧵 1/9 While the group is often seen as overrepresented, our disaggregated analysis reveals stark disparities for Southeast Asians.

Joining Bluesky Austin.com-nguonly.bsky.social

1/ After residency at Mass General Hospital, I reported to Atlanta to meet my fellow CDC Epidemic Intelligence Service Officers. I have never felt so intimidated by my peers The best and the brightest, they were star clinicians, had served in disaster zones; MD/PhDs and MSF.